IOBT Quote, Financials, Valuation and Earnings

Enanta Pharmaceuticals, Inc. has a net margin of -- compared to IO Biotech, Inc.'s net margin of -123.64%. IO Biotech, Inc.'s return on equity of -297.46% beat Enanta Pharmaceuticals, Inc.'s return on equity of -85.63%.

IO Biotech, Inc. has a consensus price target of $2.46, signalling upside risk potential of 233.56%. On the other hand Enanta Pharmaceuticals, Inc. has an analysts' consensus of $19.13 which suggests that it could grow by 15.21%. Given that IO Biotech, Inc. has higher upside potential than Enanta Pharmaceuticals, Inc., analysts believe IO Biotech, Inc. is more attractive than Enanta Pharmaceuticals, Inc..

IO Biotech, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Enanta Pharmaceuticals, Inc. has a beta of 0.965, suggesting its less volatile than the S&P 500 by 3.527%.

IO Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enanta Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech, Inc. pays -- of its earnings as a dividend. Enanta Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

IO Biotech, Inc. quarterly revenues are --, which are smaller than Enanta Pharmaceuticals, Inc. quarterly revenues of $15.1M. IO Biotech, Inc.'s net income of -$8.4M is higher than Enanta Pharmaceuticals, Inc.'s net income of -$18.7M. Notably, IO Biotech, Inc.'s price-to-earnings ratio is -- while Enanta Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech, Inc. is -- versus 5.42x for Enanta Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

GT Biopharma, Inc. has a net margin of -- compared to IO Biotech, Inc.'s net margin of --. IO Biotech, Inc.'s return on equity of -297.46% beat GT Biopharma, Inc.'s return on equity of -626.24%.

IO Biotech, Inc. has a consensus price target of $2.46, signalling upside risk potential of 233.56%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 846.75%. Given that GT Biopharma, Inc. has higher upside potential than IO Biotech, Inc., analysts believe GT Biopharma, Inc. is more attractive than IO Biotech, Inc..

IO Biotech, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

IO Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

IO Biotech, Inc. quarterly revenues are --, which are smaller than GT Biopharma, Inc. quarterly revenues of --. IO Biotech, Inc.'s net income of -$8.4M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, IO Biotech, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech, Inc. is -- versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -- compared to IO Biotech, Inc.'s net margin of 33.68%. IO Biotech, Inc.'s return on equity of -297.46% beat Merck & Co., Inc.'s return on equity of 39.63%.

IO Biotech, Inc. has a consensus price target of $2.46, signalling upside risk potential of 233.56%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 3.37%. Given that IO Biotech, Inc. has higher upside potential than Merck & Co., Inc., analysts believe IO Biotech, Inc. is more attractive than Merck & Co., Inc..

IO Biotech, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

IO Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.08% to investors and pays a quarterly dividend of $0.85 per share. IO Biotech, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IO Biotech, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. IO Biotech, Inc.'s net income of -$8.4M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, IO Biotech, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 14.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech, Inc. is -- versus 4.20x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to IO Biotech, Inc.'s net margin of 21.32%. IO Biotech, Inc.'s return on equity of -297.46% beat Pfizer Inc.'s return on equity of 10.84%.

IO Biotech, Inc. has a consensus price target of $2.46, signalling upside risk potential of 233.56%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that IO Biotech, Inc. has higher upside potential than Pfizer Inc., analysts believe IO Biotech, Inc. is more attractive than Pfizer Inc..

IO Biotech, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

IO Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. IO Biotech, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

IO Biotech, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. IO Biotech, Inc.'s net income of -$8.4M is lower than Pfizer Inc.'s net income of $3.6B. Notably, IO Biotech, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech, Inc. is -- versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.